tirzepatide news update The FDA says the Zepbound shortage is over. That's rattling the weight loss industry FDA says the tirzepatide weight-loss

The registration Anvisa issued on July 29, 2026 is a safety and efficacy certification it confirms the drugs work and meet quality standards, but does not authorize their commercial sale or set a price

Tier 3: No Meaningful COA Avoid Red flags: No COA available, COA only shows a purity figure without methodology, no lab name, no batch number, or marketed as a dietary supplement implying FDA oversight that does not exist

Her work ensures clients benefit plans are built accurately, a vital piece of pharmacy benefit management

Clinical data suggest semaglutides weight loss is primarily driven by reduced energy intake, with no significant changes in energy expenditure noted in trials